Results 161 to 170 of about 88,362 (256)

Adult granulosa cell tumours of the testis analogous to ovarian counterparts are exceptionally rare: analysis of a multicentric series and review of the literature

Histopathology, Volume 88, Issue 4, Page 831-842, March 2026.
Assessment of twenty testicular AGCTs with two different next‐generation sequencing (NGS) panels reveals differences with ovarian AGCTs, including absence of hotspot FOXL2 variants. Aims Testicular adult granulosa cell tumours (AGCTs) are rare and show several clinical–pathological differences with their ovarian counterparts.
Costantino Ricci, Dario de Biase, Thais Maloberti, Agnese Orsatti, Thomas M Ulbright, Muhammad T Idrees, Esther Oliva, Kristine Cornejo, João Lobo, Kvetoslava Michalova, Maria Rosaria Raspollini, Sean R Williamson, Geert JLH van Leenders, Chia‐Sui Kao, Fiona Maclean, Ankur R Sangoi, Adeboye O Osunkoya, Michelangelo Fiorentino, Antonio De Leo, Giovanni Tallini, Andres Martin Acosta   +20 more
wiley   +1 more source

Skin lesions as the first manifestation of follicular lymphoma

Przegląd Dermatologiczny, 2023
Julia Nowowiejska, Anna Baran, Iwona Flisiak   +2 more
doaj   +1 more source

Towards a chemo-free approach for follicular lymphoma. [PDF]

Br J Haematol
Luminari S, Barbieri E, Nizzoli ME.
europepmc   +1 more source

RB1 inactivation in cutaneous carcinomas

Histopathology, Volume 88, Issue 4, Page 769-789, March 2026.
Among skin carcinomas, recurrent RB1 inactivation is observed in Merkel cell carcinoma, in a subset of squamous cell carcinoma with bowenoid morphology, in sebaceous carcinoma and in the recently described Wnt/beta‐catenin rosette‐forming carcinoma.
Tiffany Liv, Antoine Touzé, David Schrama, Serge Guyétant, Mahtab Samimi, Michael T Tetzlaff, Benjamin A Wood, Paul W Harms, Thibault Kervarrec   +8 more
wiley   +1 more source

Impact of Rituximab Maintenance on outcomes in Follicular Lymphoma: An indian experience. [PDF]

Leuk Res Rep
Pant H, Gogia A, Sharma A, Wig N, Raju Sagiraju HK, Mallick S, Gupta R, Biswas A.   +7 more
europepmc   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

International Journal of Dermatology, Volume 65, Issue 3, Page 456-463, March 2026.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos, Carina Maria Petrenciu, Alin Stefan Vizitiu, Raluca Ghețe, Umer Nadir, Adrian Lucian Baican, Stanislav N. Tolkachjov   +6 more
wiley   +1 more source

Aggressive Follicular Lymphoma of the Breast: An Unusual Suspect. [PDF]

Cureus
Ali K, Mikulas C, Quan A, Rashid T, Quan WJ.   +4 more
europepmc   +1 more source

CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target

Advanced Science, Volume 13, Issue 8, 9 February 2026.
This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang, Huijie Bian, Zhi‐Nan Chen   +2 more
wiley   +1 more source

Tafasitamab in relapsed follicular lymphoma: promise and remaining question. [PDF]

Ann Med Surg (Lond)
Irshad NU, Sheikh M, Riaz L, Sarfraz W, Imran SB.   +4 more
europepmc   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source